Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that BioStratum and Otsuka will enter the diabetic nephropathy market within the next ten years with new advanced glycation end product (AGE) inhibitors. Thought leaders believe AGE inhibitors hold promise in the treatment of diabetic nephropathy patients, despite the historical failure of agents in the class previously under development for this and other indications.

"BioStratum's pyridoxamine will benefit from an early launch and will become the dominant agent in the AGE inhibitor class, capturing approximately 15% of total major-market diabetic nephropathy sales in 2013," said Kat Lynch, analyst at Decision Resources.

The new Pharmacor study entitled Diabetic Nephropathy also finds that experts are guarded about the potential of new therapies for the disease.

"With little clinical data available to assess emerging agents, and firmly established, long-standing treatment practices, interviewed thought leaders predict they will be slow to embrace any of the agents currently in development for the treatment of diabetic nephropathy," continued Mrs. Lynch.

About Diabetic Nephropathy

Diabetic nephropathy is the leading cause of end-stage renal disease in the United States, Europe, and Japan. It is a life-threatening complication of diabetes that affected nearly 8 million diagnosed diabetics in the seven major pharmaceutical markets (United States, France, Germany, Spain, Italy, Japan, and the United Kingdom) in 2003. Despite the current availability of effective treatments, many patients will nevertheless progress to renal failure and require dialysis and/or renal transplantation.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

InterStudy's Competitive Edge Reports Now Provide HMO and PPO Market Data

View Now